ZYTIGA is an oral androgen biosynthesis inhibitor that inhibits androgen producing CYP17 enzyme complex.
According to a randomized, placebo-controlled Phase 3 study treatment with ZYTIGA in combination with prednisone resulted in a 35% reduction in the risk of death.
In an updated analysis, results were consistent with those from the interim analysis with a 4.6 month difference between the two arms in median survival (15.8 months vs. 11.2 months [HR = 0.74]).
Memorial Sloan-Kettering Sidney Kimmel Center for Urologic and Prostate Cancers Genitourinary Oncology Service chief Howard Scher said the efficacy and safety profile of abiraterone acetate, as well as its oral, once-daily formulation, promises a new option in the treatment of metastatic prostate cancer.